AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

KYMR · NASDAQ · Biotechnology

Kymera Therapeutics (KYMR)

Develops oral protein degraders for immunology and partnered oncology programs.

$114.72

vs last close−7.34 (−6.01%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	5	48	10	26	4	7	22	11	3	3	34	65
Cost of revenue	0	0	0	0	0	0	0	2	74	−76	0	0
Gross profit	5	48	10	26	4	7	22	9	−71	79	34	65
	62	67	68	77	76	88	97	94	21	177	119	141
Research & development	48	53	49	59	60	72	80	78	74	84	98	119
	14	14	14	17	15	16	16	18	17	17	20	21
General & administrative	14	14	14	17	15	16	16	18	17	17	20	21
Other expenses	0	0	5	0	0	0	0	−2	−70	76	0	0
Operating income	−58	−19	−58	−51	−72	−81	−74	−85	−93	−98	−84	−76
	5	5	9	9	10	10	9	8	10	11	15	14
Interest income	5	5	9	9	10	10	9	8	10	11	15	14
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−5	−5	−9	−9	−10	−10	−9	−8	−10	−11	−15	−14
Income before tax	−53	−14	−49	−42	−62	−71	−66	−77	−82	−87	−69	−61
Net income from continuing operations	−53	−14	−49	−42	−62	−71	−66	−77	−82	−87	−69	−61
Net income	−53	−14	−49	−42	−62	−71	−66	−77	−82	−87	−69	−61
EPS, basic	−$0.90	−$0.25	−$0.69	−$0.58	−$0.82	−$0.88	−$0.82	−$0.95	−$0.94	−$0.98	−$0.71	−$0.62
EPS, diluted	−$0.90	−$0.25	−$0.69	−$0.58	−$0.82	−$0.88	−$0.82	−$0.95	−$0.94	−$0.98	−$0.71	−$0.62
Weighted average shares, basic	58	59	71	73	76	80	80	80	87	84	98	98
Weighted average shares, diluted	58	59	71	73	76	80	80	80	87	84	98	98
EBITDA	−52	−13	−47	−40	−60	−69	−63	−74	−79	−85	−67	−61
Depreciation & amortization	1	1	1	2	2	2	2	2	3	2	2	0
EBIT	−53	−14	−48	−42	−62	−71	−66	−77	−82	−87	−69	−61